CD28 and non-Hodgkin lymphoma: During R/R NHL treatment, CD19 CAR-T cells with 4-1BB co-stimulatory domain had superior safety profiles and fewer adverse events but was less effective to the disease compared with CD28 as a co-stimulatory molecule in numerous studies (18–21).